Fluphenazine, a first-generation (typical) antipsychotic in the phenothiazine class, carries a wide range of side effects, with movement disorders being the most clinically significant. Used primarily for schizophrenia and other psychotic conditions, fluphenazine works by blocking dopamine receptors in the brain, and that mechanism is also the root cause of most of its unwanted effects. Some are merely uncomfortable, others can be life-threatening, and a few can become permanent if not caught early.
How the Drug Works and Why That Matters for Side Effects
Fluphenazine exerts its antipsychotic effect by blocking dopamine receptors, particularly the D2 subtype, in the brain. Research has shown it also blocks D1 receptors, and this dual blockade triggers widespread changes in brain chemistry, particularly in the basal ganglia, the brain region that coordinates smooth, voluntary movement.1PubMed Central. Modulation of basal ganglia neurotransmission by the classical antipsychotic fluphenazine is due in part to the blockade of dopamine D1-receptors Because dopamine is also involved in hormone regulation, muscle tone, heart rhythm, and temperature control, blocking it produces side effects that reach well beyond the brain’s thought-processing centers. Nearly every major side effect of fluphenazine traces back to dopamine blockade somewhere in the body.
Movement Disorders Are the Hallmark Problem
The side effects that most define fluphenazine, and first-generation antipsychotics generally, are movement-related problems collectively called extrapyramidal symptoms. These fall into several distinct patterns depending on when they appear and what they look like.
Acute dystonia tends to show up within hours or days of starting the drug or increasing the dose. It involves sustained, involuntary muscle contractions that can twist the neck, lock the jaw, or force the eyes upward. It is alarming when it happens but generally responds quickly to treatment. Drug-induced parkinsonism, which looks much like Parkinson’s disease, develops more gradually over weeks. It causes a shuffling walk, stiffness, tremor, and a mask-like facial expression. Akathisia is an intensely uncomfortable inner restlessness that makes sitting still feel nearly impossible. People experiencing it often pace, shift their weight, or rock back and forth. It is one of the most distressing side effects and a common reason people stop taking the medication.
In a six-month comparison trial, patients receiving fluphenazine decanoate (the long-acting injectable form) displayed more extrapyramidal motor symptoms and required roughly twice the amount of anti-parkinsonian medication compared to those on haloperidol decanoate.2PubMed. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention That finding is worth noting because haloperidol is itself considered a high-potency antipsychotic with substantial movement side effects, so fluphenazine coming out worse on that measure underscores how prominent these problems are.
Anticholinergic medications such as benztropine and trihexyphenidyl can treat drug-induced parkinsonism and acute dystonia effectively. However, they are not recommended for akathisia or tardive dyskinesia and come with their own side effects, including urinary retention, dry mouth, constipation, and impaired cognition, the latter being especially concerning in older adults.3PubMed Central. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders
Tardive Dyskinesia and the Risk That Doesn’t Go Away
Tardive dyskinesia is the movement side effect that worries clinicians most because it can become permanent. It typically appears after months or years of continuous use and involves repetitive, involuntary movements, most often around the mouth and face: lip smacking, tongue protrusions, chewing motions, grimacing. It can also affect the limbs and trunk. Unlike the acute movement problems described above, tardive dyskinesia does not reliably improve when the drug is stopped, and anticholinergic medications do not help.4PubMed Central. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders
The risk of developing tardive dyskinesia is not the same for everyone, and genetics play a measurable role. Research on the CYP2D6 gene, which encodes a liver enzyme responsible for metabolizing fluphenazine and many other drugs, found that people carrying one mutated copy of this gene developed tardive dyskinesia at a substantially higher rate than those without mutations. In one study of schizophrenia patients, the incidence of tardive dyskinesia was about 81% among those heterozygous for a CYP2D6 mutation, compared with roughly 46% in those without such mutations.5PubMed. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia The likely explanation is that reduced enzyme activity means the drug lingers at higher concentrations in the body, increasing cumulative dopamine receptor blockade over time. Pharmacogenomic testing for CYP2D6 status is available, though it is not yet routine before prescribing fluphenazine in most clinical settings.
Older adults, women, and people with mood disorders rather than schizophrenia are also generally considered at higher risk for tardive dyskinesia. The longer someone takes fluphenazine, the higher the cumulative risk, which is one reason clinicians aim for the lowest effective dose.
Neuroleptic Malignant Syndrome
The most dangerous side effect of fluphenazine is neuroleptic malignant syndrome, a rare but potentially fatal reaction. It involves extreme hyperthermia, severe “lead-pipe” muscle rigidity, autonomic instability (wild swings in blood pressure, heart rate, and sweating), and fluctuating consciousness.6General Pharmacology: The Vascular System. Pathogenesis and treatment of neuroleptic malignant syndrome The muscle breakdown caused by the rigidity can release enough protein into the bloodstream to damage the kidneys.
A published case report describes a 21-year-old man with schizophrenia who developed this syndrome after receiving a 25 mg injection of fluphenazine decanoate on top of his existing regimen of thioridazine and haloperidol. He arrived in the intensive care unit with an oral temperature over 40°C, a heart rate of 140, severe rigidity, and shaking tremors. His lab work showed elevated creatine kinase and liver enzymes, along with kidney dysfunction.7PubMed. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient Risk factors for this reaction include a history of previous episodes, dehydration, agitation, use of multiple antipsychotics at once, and the route of administration, with injections posing particular concern because the drug cannot be “taken back” once given.8PubMed. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient
Neuroleptic malignant syndrome is a medical emergency. Treatment involves immediately stopping the antipsychotic, aggressive cooling, intravenous fluids, and sometimes medications like dantrolene or bromocriptine. Anticholinergic medications are not effective for this condition.9PubMed Central. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders Anyone taking fluphenazine who develops a sudden high fever with muscle stiffness should seek emergency care immediately.
Heart Rhythm and Blood Pressure Effects
Fluphenazine can affect the cardiovascular system in ways that range from mildly annoying to genuinely dangerous. Orthostatic hypotension, a drop in blood pressure when standing up, is one of the more common complaints. It causes lightheadedness or dizziness and raises the risk of falls, especially in older adults. Sinus tachycardia, a faster-than-normal resting heart rate, is another recognized cardiovascular effect.10PubMed Central. Fluphenazine decanoate-induced bradycardia: A case report
More worrying is fluphenazine’s potential to disrupt the heart’s electrical conduction. In a case analysis using a standardized causality assessment, cardiac conduction abnormalities were rated as a possible adverse event tied to fluphenazine, particularly when doses were being increased. The concern centers on a condition called QT prolongation, which can progress to a dangerous heart rhythm called Torsades de Pointes.11PubMed Central. Cardiovascular Risks of Fluphenazine in a Patient With Schizophrenia Interestingly, bradycardia (an abnormally slow heart rate) has also been reported with the long-acting injectable form, which is a less expected cardiovascular effect for this drug class.12PubMed Central. Fluphenazine decanoate-induced bradycardia: A case report
People with pre-existing heart conditions, those taking other medications that affect heart rhythm, and those on higher doses of fluphenazine are at greater risk. Baseline and periodic electrocardiograms are considered reasonable monitoring in practice, though specific guidelines vary.
Hormonal Disruption From Prolactin Elevation
Dopamine normally acts as a brake on prolactin release from the pituitary gland. When fluphenazine blocks dopamine receptors there, prolactin levels rise, often substantially. This condition, called hyperprolactinemia, produces a cluster of symptoms that many patients find distressing but may not immediately connect to their medication.
In women, elevated prolactin can cause missed or irregular periods, breast tenderness, and unwanted breast milk production. In men, it can lead to breast tissue enlargement, sexual dysfunction, and reduced libido. Over the long term, persistently high prolactin may contribute to reduced bone density in both sexes, which is a concern for patients on long-term maintenance therapy.
One notable feature of fluphenazine’s prolactin effect is its duration. A single injection of fluphenazine decanoate can elevate prolactin levels for up to 28 days.13Therapeutics and Clinical Risk Management. Pharmacological causes of hyperprolactinemia That extended timeline matters because if a patient develops symptoms, switching medications will not produce a rapid reversal. Case reports have explored adding aripiprazole, a newer antipsychotic with partial dopamine agonist activity, to counteract fluphenazine-induced prolactin elevation with some success.14South East Asia Journal of Public Health. Aripiprazole is effective in hyperprolactinemia secondary to use of Fluphenazine
Skin and Eye Problems
Phenothiazines as a class are associated with photosensitivity, meaning the skin burns more easily in sunlight. With fluphenazine specifically, both ocular and skin disorders are recognized side effects.15PubMed Central. In vitro melanogenesis inhibition by fluphenazine and prochlorperazine in normal human melanocytes lightly pigmented Long-term use can lead to a slate-gray or purplish discoloration of sun-exposed skin, and deposits in the lens and cornea of the eye have been documented with prolonged phenothiazine therapy. These ocular deposits can, in rare cases, progress to impaired vision.
Laboratory research has shown that fluphenazine directly inhibits melanin production in human skin cells, which helps explain the pigmentary changes some patients experience.16PubMed Central. In vitro melanogenesis inhibition by fluphenazine and prochlorperazine in normal human melanocytes lightly pigmented Patients on long-term treatment are often advised to wear sunscreen and sunglasses and to have periodic eye examinations.
The Long-Acting Injectable and Why It Complicates Things
Fluphenazine is available in two long-acting injectable forms, fluphenazine decanoate and fluphenazine enanthate, both designed to be given every few weeks rather than taken daily by mouth. These formulations are especially useful for patients who have difficulty adhering to a daily pill regimen, which is common in schizophrenia. But the injectable creates a specific problem: once the drug is injected into muscle tissue, it is slowly released over weeks, and there is no way to remove it if a serious side effect develops.
This matters most for neuroleptic malignant syndrome, as described earlier. When the condition was triggered by an intramuscular injection of fluphenazine decanoate, the treating team could not simply stop the drug since it was already in the patient’s body and would continue releasing for weeks.17PubMed. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient The same irreversibility applies to other serious reactions like severe dystonia or cardiac problems. Clinicians sometimes start patients on oral fluphenazine first to confirm tolerability before switching to the injectable, precisely because the oral form can be stopped immediately if something goes wrong.
The two injectable formulations differ somewhat in their duration of action and side effect profiles. Fluphenazine decanoate generally lasts longer and has become the more widely used of the two, while fluphenazine enanthate has a somewhat shorter duration.18American Journal of Psychiatry / PubMed Central. Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects
Sedation and Other Common Complaints
Fluphenazine is considered a “high-potency” phenothiazine, meaning it is effective at lower doses compared to “low-potency” relatives like chlorpromazine. High-potency antipsychotics generally cause less sedation and fewer anticholinergic effects (dry mouth, constipation, blurred vision, urinary retention) than low-potency ones, but they cause more movement problems. That said, “less sedation” does not mean “no sedation.” Drowsiness remains a common complaint, particularly early in treatment or after dose increases. Dry mouth and constipation do occur, just less frequently than with chlorpromazine.
Weight gain and metabolic changes such as elevated blood sugar and cholesterol are associated with antipsychotics as a class, though fluphenazine tends to cause less weight gain than many second-generation antipsychotics. For patients on long-term maintenance, periodic monitoring of weight, blood sugar, and lipid levels remains reasonable practice.
Use During Pregnancy
Fluphenazine use during pregnancy carries risks to the newborn. Both fluphenazine and the related phenothiazine chlorpromazine have been shown to cause extrapyramidal symptoms and respiratory distress in infants born to mothers who were treated with these medications.19PubMed Central. The potential risks of commonly prescribed antipsychotics: during pregnancy and lactation Extrapyramidal symptoms in a newborn can include abnormal muscle tone, tremors, and feeding difficulties. These effects are typically self-limiting but can require monitoring in a neonatal unit.
The decision to use fluphenazine during pregnancy involves weighing these neonatal risks against the serious dangers of untreated psychosis in the mother, including the risk of self-harm, inability to care for oneself, and harm to the pregnancy itself. There is no risk-free option for a pregnant woman who needs antipsychotic treatment, and the choice involves careful discussion between the patient, her psychiatrist, and her obstetrician. Many clinicians try to use the lowest effective dose and avoid the long-acting injectable during the third trimester, since it cannot be quickly discontinued near delivery.
Who Is Most Vulnerable to Side Effects
Certain groups face disproportionate risk. Older adults are more susceptible to orthostatic hypotension (and the resulting falls), tardive dyskinesia, and anticholinergic cognitive effects. People with Lewy body dementia or Parkinson’s disease can experience dangerous worsening of motor symptoms. Individuals with a personal or family history of QT prolongation are at heightened risk for cardiac complications.
As discussed earlier, people who are poor metabolizers of CYP2D6 substrates effectively receive a higher drug exposure at any given dose, increasing their vulnerability to dose-dependent side effects like tardive dyskinesia.20PubMed. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia People of certain ethnic backgrounds have higher rates of CYP2D6 variants that reduce enzyme activity, which means the risk is not evenly distributed across populations.
Polypharmacy deserves particular attention. The case of neuroleptic malignant syndrome described earlier involved a patient already taking two other antipsychotics when fluphenazine was added. Combining multiple dopamine-blocking drugs amplifies the risk of virtually every side effect discussed in this article, and yet it remains surprisingly common in clinical practice, particularly in inpatient psychiatric settings.
Why Fluphenazine Is Still Used
Given this list of side effects, it is fair to ask why anyone still prescribes fluphenazine. The answer is partly practical and partly clinical. Fluphenazine is inexpensive and available as a long-acting injection, which addresses one of the most persistent problems in schizophrenia treatment: inconsistent medication adherence. A patient who receives an injection every two to four weeks is continuously protected against psychotic relapse in a way that a patient who forgets daily pills is not. For some individuals, especially those with a history of repeated hospitalizations due to nonadherence, fluphenazine decanoate remains a genuinely valuable option. The newer long-acting injectables (paliperidone palmitate, aripiprazole lauroxil) are alternatives, but they cost dramatically more, placing them out of reach for many patients and healthcare systems worldwide.
Fluphenazine also remains in the World Health Organization’s Model List of Essential Medicines, reflecting its continued importance in settings where newer agents are not available. The side effect profile is real and consequential, but for patients whose psychotic symptoms respond well to the drug and who tolerate it without severe movement problems, the trade-off can be worthwhile, especially when it is the difference between living in the community and cycling through psychiatric crises.